Phathom Pharmaceuticals is a biopharmaceutical company dedicated to transforming the treatment of gastrointestinal (GI) diseases. With exclusive rights in the United States, Europe, and Canada to vonoprazan—a first-in-class potassium-competitive acid blocker (PCAB)—Phathom is working to transform the treatment of acid-related disorders. Our current portfolio includes: VOQUEZNA® (vonoprazan) tablets, approved for the treatment of heartburn associated with Non-Erosive GERD, as well as the healing and maintenance of healing of Erosive GERD; VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules), approved for the treatment of H. pylori infection in adults. Beyond our commercialized products, we are advancing a pipeline focused on innovative treatments for other acid-related GI disorders, including Eosinophilic Esophagitis (EoE).
